Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia

Table 2 The baseline characteristics of individual study

Study	Group	Age (years)	BMI (kg/m²)	PV (ml)	PSA (ng/ml)	IPSS	Qmax (ml/s)	PVR (ml)
Hong et al. (2010) [20]	Combination	66.60 ± 7.10	24.90 ± 3.00	≥ 30	3.0 ± 3.90	> 7	< 15	unmentioned
Hong et al. (2010) [20]	Tamsulosin	65.70 ± 8.50	24.60 ± 2.30	≥ 30	2.6 ± 2.30	> 7	< 15	unmentioned
Joo et al. (2012) [21]	Combination	65.85 ± 7.77	unmentioned	37.26 ± 13.22	1.77 ± 1.40	19.94 ± 6.14	11.13 ± 5.08	49.16 ± 23.52
Joo et al. (2012) [21]	Tamsulosin	65.79 ± 8.87	unmentioned	36.63 ± 13.16	1.70 ± 1.23	19.95 ± 5.54	11.32 ± 5.77	49.19 ± 22.04
Roehrborn et al. (2014) [22]	Combination	66.00 ± 7.05	unmentioned	54.7 ± 23.51	4.00 ± 2.05	16.60 ± 6.35	10.90 ± 3.61	68.20 ± 66.12
Roehrborn et al. (2014) [22]	Tamsulosin	66.20 ± 7.00	unmentioned	55.8 ± 24.18	4.00 ± 2.08	16.40 ± 6.10	10.70 ± 3.66	67.70 ± 65.14
Roehrborn et al. (2015) [23]	Combination	66.30 ± 7.78	27.28 ± 3.53	51.0 ± 18.17	3.90 ± 2.00	13.20 ± 4.06	unmentioned	unmentioned
Roehrborn et al. (2015) [23]	Tamsulosin	66.20 ± 7.34	27.94 ± 3.77	52.6 ± 19.57	3.70 ± 1.91	12.90 ± 3.95	unmentioned	unmentioned
Choi et al. (2016) [24]	Combination	61.86 ± 1.26	unmentioned	41.05 ± 2.67	1.31 ± 0.15	20.04 ± 0.62	11.81 ± 0.29	31.08 ± 2.76
Choi et al. (2016) [24]	Tamsulosin	61.94 ± 1.23	unmentioned	40.34 ± 1.43	1.35 ± 0.12	19.09 ± 0.60	11.40 ± 0.38	31.00 ± 3.44

Data presented as mean ± SD
IPSS International Prostate Symptom Score, Qmax maximum urine flow rate, PSA Prostate Specific Antigen, PV Prostate Volume, PVR Post-Void Residual, BMI Body Mass Index

ISSN: 1471-2490